PM20D1 is a quantitative trait locus associated with Alzheimer's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29736028.
- Also identified by DOI 10.1038/s41591-018-0013-y.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors <sup>1</sup> , the latter likely being mediated by epigenetic mechanisms <sup>2</sup> . In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology <sup>3</sup> , but a causal relationship remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations, which provide mechanistic insights for a particular risk gene but often lack the statistical power of GWAS <sup>4</sup> . Here, combining both approaches, we report a previously unidentified association of the peptidase M20-domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation and expression quantitative trait locus coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CCCTC-binding-factor-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults at symptomatic stages in the APP/PS1 mouse model of AD and in human patients with AD who are carriers of the non-risk haplotype. In line, genetically increasing or decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD.
Medical subject headings
- Alzheimer Disease
- Amidohydrolases
- Quantitative Trait Loci